Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial.
Govi
Silvia
S
Dognini
Giuseppina P
GP
Licata
Giada
G
Crocchiolo
Roberto
R
Resti
Antonio Giordano
AG
Ponzoni
Maurilio
M
Ferreri
Andrés J M
AJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use*; D003230:Conjunctival Neoplasms / Q000188:drug therapy; D005134:Eye Neoplasms / Q000188:drug therapy*; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D017291:Clarithromycin